All
Novel Agents, Including Immunotherapy, Look to Conquer Advanced Liver Cancer
April 27th 2016A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma (HCC), including a host of targeted therapies and various immune checkpoint inhibitors.
Immunotherapy Combination Shows Benefit in Phase 2 Advanced Melanoma Trial
April 25th 2016The combination of Yervoy and Opdivo showed a 42 percent improvement in overall survival compared with Yervoy monotherapy for patients with advanced melanoma in a two-year assessment of the phase 2 CheckMate-069 trial.